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Abstract 
 
Background: Left ventricular hypertrophy (LVH) is a potent risk factor for sudden death and 
congestive heart failure. 
Methods: We tested the effect of sorafenib, a multikinase inhibitor (10mg/kg, given orally, 
starting 2 days prior to banding, till sacrifice on day 14), on the development of LVH following 
aortic banding in rats. 
Results: The latter resulted in significant LVH caused by both an increase in cardiomyocyte 
volume and interstitial collagen deposition. The observed LVH was entirely blocked by sorafenib 
downregulating both of these components. LVH was associated with PDGF-BB and TGFβ1 
overexpression, as well as phosphorylation of c-raf and ERK1/2. Additionally, the transcription 
factors c-myc and c-fos leading to proliferation as well as the hypertrophy-inducing transcription 
factor GATA4 and its regulated gene ANP were all upregulated in response to aortic banding. 
All these overexpressions and upregulations were inhibited upon sorafenib treatment. 
Conclusion: We show that sorafenib exhibits a regulatory role on the occurrence of LVH 
following AB in rats by blocking the rise in growth factors PDGF-BB and TGFβ1, activation of 
the corresponding c-Raf-ERK1/2 signaling pathway and effector mechanisms, including GATA4 
and ANP. This effect of sorafenib may be of clinical importance in modulating the maladaptive 
hypertrophic response to pressure overload. 
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Background 
 
Human left ventricular hypertrophy (LVH) is a feature of myocardial remodeling that may 
occur as a consequence of compensatory mechanisms to manage increased pressure overload 
as observed in essential arterial hypertension or aortic valve stenosis. LVH is a potent risk 
factor for cardiac arrhythmias and sudden death, diastolic dysfunction and congestive heart 
failure [1]. Adult cardiomyocytes are unable to divide and respond to stress and growth stimuli 
by increasing their rate of protein synthesis, resulting in increased cell volume [2, 3]. In addition 
to cardiomyocyte hypertrophy, pressure-overload causes interstitial cell proliferation and 
extracellular matrix production with increased perivascular and interstitial collagen deposition in 
spontaneously hypertensive rats [4]. Pressure-overload results in the local release of ligands in 
cardiac tissue, including growth factors such as platelet-derived growth factor (PDGF) activating 
its tyrosine kinase receptors [5, 6], and transforming growth factor β (TGF β) activating its 
serine-threonine kinase receptors [7-9]. The signaling pathways include the cascade of c-Raf 
(serine-threonine kinases) and its downstream substrates mitogen-activated protein kinases 
(MAPK) [5, 10, 11]. The extracellular signal-regulated kinases (ERK)1/2, a subgroup of MAPK, 
play a critical role in the regulation of gene expression leading to cardiac hypertrophy [12]. 
Activation of ERK1/2 by phosphorylation has been associated with upregulation of cardiac 
transcription factors c-myc, c-fos and GATA4 [5, 10]. GATA4 is a critical transcription factor of 
most cardiac-expressed structural genes and hypertrophy-related genes, including the atrial 
natriuretic peptide (ANP) gene [13, 14]. In humans, mutations in c-Raf are associated with 
cardiac hypertrophy in genetic disorders such as Noonan syndrome suggesting an important 
role of c-Raf in pathophysiological modulation of cardiac hypertrophy [15]. 
 
Data accumulated from cancer research indicate a variety of theoretical parallels 
between signaling pathways that drive tumorigenesis [16, 17], and those that regulate cardiac 
hypertrophy [5, 10, 11], a major common signal transduction pathway being represented by the 
Raf-ERK1/2 cascade. Sorafenib is a multiprotein kinase inhibitor used as an antineoplasic 
agent, inhibiting the Raf serine/threonine kinase, as well as the VEGFR and PDGFR-β tyrosine 
kinases, and the c-kit tyrosine kinase. Recent studies show that sorafenib prevents the 
progression of right ventricular hypertrophy due to pulmonary hypertension in a rodent 
experimental model [18, 19]. This prompted us to evaluate the effect of sorafenib on the 
development of left ventricular hypertrophy in a rodent experimental model of mechanically-
induced pressure overload obtained by banding of the supra-renal aorta. 
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Methods 
 
Experimental design 
Animals. Male Lewis rats (Harlan, Holland) weighing 90-110g were used and received humane 
care in strict accordance with the recommendations in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. The protocol was approved by the 
Committee on the ethics of Animal Experiments of the Canton Zurich, Switzerland (Permit 
Number 122/2008). All surgery was performed under sodium pentobarbital anesthesia, and all 
efforts were made to minimize suffering. Animals were maintained in standard housing 
conditions with dry diet and water available ad libitum.  
 
Treatment groups. Animals were randomly assigned to receive sorafenib 10 mg/kg (Bayer, 
Germany) or vehicle (NaCl 0.9%) once daily by gavage, starting 2 days prior to surgery and 
continuing for 14 days thereafter. They were killed 12-14 hours after the last gavage, and blood 
and tissue harvested for subsequent analyses. 
 
Surgery. Sorafenib- or solvent-treated animals were further randomly assigned to undergo 
aortic banding (AB) or sham operation. In banding animals, a median laparotomy was 
performed, the supra-renal aorta dissected free, and a ring of polyurethane (1 mm diameter) 
placed around the aorta and secured with 7/0 Prolene as described [20]. In control sham 
animals, a median laparotomy was performed and the supra-renal aorta dissected free without 
any placement of a ring. After euthanasia, the left myocardial ventricle was rapidly excised and 
weighed before tissue processing. The ventricular weight to body weight (VW/BW) ratio was 
used as the macroscopic indicator of left ventricular hypertrophy. 
 
Histological analysis 
After excision, the left myocardial ventricle was rapidly fixed in 10% formalin, and paraffin-
embedded. Sections (7-µm) were processed for hematoxylin and eosin (H&E), and van 
Gieson’s staining (Elastica van Gieson Kit, Merck, Darmstadt, Germany) to detect collagen 
deposition (red color) indicative of cardiac fibrosis [21]. The stained sections were visualized 
under light microscopy (Vanox-S, Olympus, Tokyo, Japan), and photographed with a digital 
camera (U-PMTVC, Olympus, Tokyo, Japan). The cross-sectional area of cardiomyocytes was 
measured using the ImageJ 1.30v Software system in at least 10 different areas for each 
section. Results were obtained from 2-4 sections per rat for a total of 5 rats selected at random 
from the various treatment groups. 
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PDGF-BB and TGF-β1 ELISA  
The ventricular levels of PDGF-BB and TGF-β1 were determined by using commercial ELISA 
kits (R&D Systems, Minneapolis, MN) according to the manufacturer’s recommendations. 
Briefly, 100 mg of snap-frozen ventricle tissue was homogenized in 500 µl of lysis buffer 
containing 50 mM Tris HCl [pH 7.5], 150 mM NaCl, 10 mM EDTA, 0.25% Triton X-100, 0.1% 
NP-40, 1 mM PMSF and cocktail protease inhibitors. The lysates were clarified at 14,000g for 
15 min at 4°C. ELISA levels were normalized to the total protein level (BCA Protein Assay kit, 
Pierce, Rockford, USA) for each sample. All measurements were performed in duplicate. 
 
Reverse transcription and quantitative polymerase chain reaction (RT-qPCR) 
Total RNA was extracted from the ventricular myocardium using RNeasy® Mini kit, including 
DNase treatment (Qiagen, Basel, Switzerland). Total RNA (2.5 µg) was reverse transcribed 
using a High-Capacity cDNA Archive Kit (Applied Biosystems, Rotkreuz, Switzerland) and 
MultiScribe reverse transcriptase (50 units/µl), random hexamers, dNTPs, and RNase inhibitor 
(20 units/µl) (all from Applied Biosystems). The reaction was performed in a total volume of 
25 µl in a GeneAmp PCR thermocycler (Applied Biosystems) at 25°C for 10 min, followed by 2 
hours at 37°C, and 10 min at 70°C. Samples without enzyme in the RT reaction were used as 
negative controls to evidence the absence of contamination with genomic DNA. Predeveloped 
primer probes were used for ANP (Rn00561661_m1), GATA4 (Rn01530459_m1), c-myc 
(Rn00561507_m1) and c-fos (Rn02396759_m1) as well as the reference genes 18S rRNA and 
GAPDH (all from Applied Biosystems). Real-time quantitative PCR was performed on an ABI 
PRISM 7500 Sequence Detection System (“TaqMan”, Applied Biosystems, Darmstadt, 
Germany) using heat-activated TaqDNA polymerase (Amplitaq Gold; Applied Biosystems). After 
an initial 2 min at 50°C, and 10 min at 95°C, the samples were submitted to 40 cycles 
comprising 15 sec at 95°C for denaturation and 60 sec at 60°C for hybridization and elongation. 
The expression of candidate genes was normalized to two reference genes (18S rRNA and 
GAPDH) giving comparable results and analyzed by the delta Ct method (Applied Biosystems). 
 
Collagen measurement 
Total soluble collagen in whole ventricle homogenate was quantified using the SirCol collagen 
assay (Biocolor, Belfast, UK). The ventricle homogenate of vehicle- or sorafenib-treated sham 
and aortic banding animals were prepared at day 14. Sirius Red (1ml), an anionic dye that 
reacts specifically with (Gly-X-Y)n tripeptide in the triple-helix sequence of mammalian collagens 
under assay conditions, was added to ventricle homogenate (10µl), and incubated under gentle 
rotation for 30 min at room temperature. After centrifugation for 10 min at 12,000g, the pelleted 
collagen-bound dye was dissolved with 1 ml of 0.5 M NaOH, and the absorbance was read at 
540 nm. Results are presented as a ratio to the total protein content. All measurements were 
performed in duplicate. 
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Western blot analysis 
The ventricle lysate was prepared in 50 mM Tris HCl [pH 7.5], 150 mM NaCl, 10 mM EDTA, 
0.25% Triton X-100, 0.1% NP-40, 1 mM PMSF and cocktail inhibitors (Roche). Protein 
concentration was measured by the BCA technique. Proteins were separated (100 µg per lane) 
on an SDS-polyacrylamide gel and transferred onto nitrocellulose membranes. Membranes 
were blocked for 1 hour at room temperature in 5% non-fat milk with 0.1% Tween 20 in Tris 
Buffer Saline (pH 7.4), and were probed overnight at 4°C with antibodies: rabbit anti-rat 
phospho-ERK1/2 (Thr202/Tyr204), mouse anti-rat total ERK1/2 (R&D biosystems; 1:1000), 
rabbit anti-rat phospho-c-Raf (Ser259) and rabbit anti-rat total c-Raf (Cell signaling; 1:1000). 
Blots were washed in TBS / 0.1%-Tween-20 for 1 hour at room temperature, and incubated with 
the appropriate HRP-conjugated secondary antibody (Jackson ImmunoResearch Laboratories; 
1/2000) in TBS / 0.1% Tween-20 / 5% nonfat milk for 1 h. Bound antibodies were visualized 
using enhanced chemiluminescence ECL kit (Perkin-Elmer, Boston, MA) according to the 
manufacturer’s instructions. Evaluation of the expression of specific proteins was performed 
with the ImageJ 1.30v Software system. 
 
Statistical analysis 
All data are results of 6 to 8 in vivo experiments, and are presented in figures as means ± SD 
(bars). An analysis of variance (ANOVA) followed by Tukey's multiple comparisons test was 
performed to analyze the modulating effect of sorafenib on the development of LVH following 
aortic banding. Statistical analyses were performed using PRISM 6 GraphPad software 
(GraphPad, La Jolla, CA, USA). P-values <0.05 were considered significant. 
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Results 
 
Left ventricular hypertrophy 
Aortic banding in vehicle-treated animals induced significant left ventricular hypertrophy 
evidenced by a 25% increase in the VW/BW ratio (sham vehicle 2.9±0.1 vs aortic banding 
vehicle 3.6±0.3 mg/kg, p<0.0001). This hypertrophic response significantly decreased after 
sorafenib treatment (sham sorafenib 2.5±0.2 vs aortic banding sorafenib 2.7±0.2, p<0.2, and 
p<0.0001 between banding vehicle and banding sorafenib) (Figure 1A). 
Aortic banding resulted in an increase in left ventricular cardiomyocyte cross-sectional area 
(sham vehicle 124.2±28.0 vs aortic banding vehicle 250.8±78.1 µm2, p<0.0001) (Figure 1B), as 
well as interstitial matrix deposition quantified by myocardial total collagen (sham vehicle 
5.1±1.2 vs aortic banding vehicle 7.5±0.4 µg/mg protein, p<0.0001) (Figure 2A and 2B) 
(p<0.0001, Figure 2B). Sorafenib entirely prevented left ventricular hypertrophy by abolishing 
both cardiomyocyte hypertrophy (sham sorafenib 117.2±19.8 vs aortic banding sorafenib 
119.7±10.9 µm2, p=0.2) and interstitial matrix deposition (sham sorafenib 5.8±1.1 vs aortic 
banding sorafenib 5.6±0.8 µg/mg protein, p=0.2, and p<0.0001 between banding vehicle and 
banding sorafenib) (Figure 2A and 2B). 
 
Growth factor expression 
Pressure overload-induced left ventricular hypertrophy was associated in vehicle-treated 
animals with significant increase in myocardial content of the pro-hypertrophic factors platelet-
derived growth factor BB (PDGF-BB) (1.3-fold increase, Figure 3A) and transforming growth 
factor β1 (TGF- β1) (2.5-fold, Figure 3B) (p<0.0001 for banding vehicle vs sham vehicle for 
both). Sorafenib treatment totally abolished the overexpression of both myocardial growth 
factors PDGF-BB (Figure 3A) and TGF-ß1 (Figure 3B) in banding animals (p<0.0001 for vehicle 
vs sorafenib). 
 
Signaling pathways 
Aortic banding resulted in a 2.2-fold increased phosphorylation of c-Raf (figure 4A) and of its 
downstream kinase ERK1/2 (1.8-fold increase, Figure 4B) (p<0.0001 for banding vehicle vs 
sham vehicle for both). Sorafenib treatment totally abolished the increased phosphorylation of c-
Raf as well as ERK 1/2 (p<0.0001 for banding vehicle vs banding sorafenib for both). 
 
Expression of the pro-proliferative and pro-hypertrophic transcription factors 
Activation of the c-Raf / ERK pathway following AB was accompanied in vehicle-treated animals 
by a significant increase in the expression of pro-proliferative nuclear transcription factor mRNA: 
1.7-fold increase in c-myc (Figure 5A) and 2.1-fold increase in c-fos (Figure 5B). Additionally, a 
2.6-fold increase in the expression of the pro-hypertrophic transcription factor GATA4 was 
observed (Figure 5C) (p<0.0001 for banding vehicle vs sham vehicle for all three factors). 
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Sorafenib totally abolished the increase in nuclear transcription factor mRNA expression, c-
myc (Figure 5A), c-fos (Figure 5B) and GATA4 (Figure 5C) in banding animals (p<0.0001). 
 
 
Expression of the pro-hypertrophic factor ANP mRNA 
Transcription of the pro-hypertrophic factor ANP is under direct control of GATA4. As expected, 
ANP mRNA expression was enhanced in vehicle-treated AB vs sham-operated animals, and 
reached a 10-fold increase after aortic banding (p<0.0001, Figure 6). Again sorafenib totally 
abolished the increase in ANP mRNA expression in banding animals (p<0.0001, Figure 6).
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Discussion 
 
Our study reports that the pressure overload induced by banding of the supra-renal aorta in 
Lewis rats resulted in significant LVH that was entirely blocked by treatment with the multikinase 
inhibitor sorafenib. This mechanically-induced pressure overload following banding closely 
mimics the clinical setting of patients with left ventricular hypertrophy due to aortic valve 
stenosis or essential arterial hypertension [3, 20]. This left ventricular hypertrophy was 
associated with PDGF-BB and TGFß1 overexpression, as well as with phosphorylation of their 
c-raf and ERK1/2 signaling pathways, all of which were downregulated by sorafenib treatment. 
The transcription factors c-myc and c-fos leading to proliferation were also upregulated in 
response to aortic banding, as well as the hypertrophy-inducing transcription factor GATA4 and 
its regulated gene ANP. All of these were downregulated by sorafenib treatment as resumed in 
Figure 7. 
 
Sorafenib was administered as a daily oral treatment at the dose of 10 mg/kg, as based on 
experimental reports in the rat [18, 19, 22], in preclinical murine models of cancer [23, 24], as 
well as in cancer patients [24]. Sorafenib is reported to inhibit in particular the Raf 
serine/threonine kinase isoforms both in vitro and in vivo in various cancer models in the mouse 
and rat [24]. This signaling pathway is described as playing a central regulatory role in the 
genesis of pressure overload-induced hypertrophy [5, 10]. In patients with Noonan and Leopard 
syndromes, presenting genetic disorders involving mutations in c-Raf, cardiac hypertrophy is 
one of developmental organ anomalies suggesting an important role of c-Raf in 
pathophysiological modulation of cardiac hypertrophy [15]. In accordance with this, we show 
here that pressure overload-induced left ventricular hypertrophy leads to the Raf cascade 
activation as evidenced by raf and ERK phosphorylation, and that this activation was blocked by 
sorafenib treatment. In addition, sorafenib is reported to inhibit the PDGFRß tyrosine kinase 
[25]. Our study adds here the new information that sorafenib decreases production of the 
PDGFRß agonist platelet-derived growth factor BB (PDGF-BB) whose expression is increased 
in animals presenting LVH following aortic banding. PDGF-BB is a growth factor that may in this 
study account for the increase in cardiomyocyte volume evidenced on histological cross-
sections. Such a role was also reported in the development of myocardial hypertrophy in 
spontaneously hypertensive rats [26]. Thus, both inhibition of c-Raf and reduction in growth 
factor production may have participated in prevention of ERK 1/2 phosphorylation and 
activation, and thereby in prevention of left ventricular hypertrophy by sorafenib. 
 
On the other hand, we show here a rise in the pro-fibrotic TGF-β1 in cardiac tissue after 
banding, and this was associated with enhanced interstitial collagen deposition, as evidenced 
by collagen measurements and van Gieson’s localization. Sorafenib inhibited both the rise in 
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TGFβ1 and collagen in cardiac tissue, thus preventing the essential component of left 
ventricular hypertrophy, i.e. interstitial collagen deposition. 
 
In line with other reports [5, 10], the phosphorylation and activation of c-Raf-ERK1/2 
signaling pathway was accompanied with up-regulation of the cardiac transcription factors c-
myc and c-fos implicated in cell proliferation and fibrosis. As expected, sorafenib down-
regulated the expression of these transcription factors, resulting from blockade of the ERK1/2 
pathway by sorafenib as reviewed in Gupta et al [3]. Indeed, phosphorylation of ERK1/2 induces 
increases in both c-myc [12] and c-fos expression [27], thereby allowing interstitial cell 
proliferation, fibrosis and collagen deposition, all of which being blocked by sorafenib. 
 
Activation of the c-Raf-ERK1/2 pathway also activates the cardiac transcription factor GATA4 in 
cardiomyocyte hypertrophy [5], which is in accordance with results reported here. A large body 
of evidence suggests that GATA4 is an important regulator of cardiac genes involved in 
pressure overload-induced cardiac hypertrophy [5, 13], including the hypertrophic agent ANP 
[14, 28]. Indeed, we show an increased expression of GATA4 and of ANP, the latter reaching 
10-fold increase following pressure overload induction in this study. In this line of evidence, our 
report clearly shows that sorafenib suppressed expression of both the pro-hypertrophic effector 
ANP and its transcription factor GATA4, and that sorafenib may therefore be an interesting 
treatment strategy for cardiac hypertrophy. 
 
The present study evidences a preventive effect of sorafenib, that was administered prior 
to induction of mechanical pressure overload during a relatively short period of 2 weeks. The 
choice of this observation period was based on the fact that in this model left ventricular 
hypertrophy was already present at one week and near maximal at two weeks following aortic 
banding (personal data). The effect of sorafenib on established left ventricular hypertrophy, and 
of its administration over a longer period in healthy and in (de)-compensated hypertrophic 
hearts will need to be further addressed, together with modifications of hemodynamic 
parameters that could account for the survival of banded animals under sorafenib. 
 
Recent evidence indicates that in some instances, cardiotoxicity occurs after use of 
kinase inhibitors including sorafenib in cancer patients [29]. With regard to sorafenib, acute 
coronary syndrome and arterial hypertension have been reported in a limited number of patients 
treated for renal cell carcinoma or melanoma [30]. The mechanisms involved in the 
cardiotoxicity of sorafenib remain presumptive. While inhibition of c-Raf by sorafenib has been 
sggested as underlying its cardiotoxicity [29], it was also submitted that sorafenib did not exert 
its damaging effects through RAF inhibition of the RAF/MEK/ERK kinase cascade [31]. Our 
finding of inhibition of phosphorylation and activation of ERK1/2 by sorafenib after aortic 
banding is in clear contrast with results observed in vitro by Hasinoff and Patel after treatment of 
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isolated cardiomyocytes by sorafenib [31]. Their study reports an increase of the basal 
phosphorylation of ERK1/2 by sorafenib in vitro. Different experimental models, as unstimulated 
in vitro (31) and in pathological situation in vivo (our study) may account for these opposed 
effects of sorafenib on c-Raf/ERK pathway. 
 
Conclusions 
We show here that sorafenib exhibits a regulatory role on the occurrence of left ventricular 
hypertrophy by blocking the rise in growth factors, and activation of the corresponding c-Raf-
ERK1/2 signaling pathway and effector mechanisms including ANP production. This effect of 
sorafenib may be of importance in modulating the maladaptive hypertrophic response to 
pressure overload. Left ventricular hypertrophy due to systemic arterial hypertension or aortic 
valve stenosis is a frequently encountered situation in the clinical setting. The main new finding 
of this study of prevention of left ventricular hypertrophy by sorafenib in banded animals could 
therefore be potentially of clinical interest. 
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Figure legends  
 
Figure 1. Sorafenib prevents the development of pressure overload-induced left 
ventricular hypertrophy (LVH) and cardiomyocyte volume. A. Following aortic banding (AB), 
LVH is anatomically evidenced by a significant rise in the ventricular weight to body weight 
(VW/BW) ratio (p<0001, ***), which was blocked by sorafenib (p<0001, ***).  B. The observed 
LVH following AB is histologically accounted for by an increase in cardiomyocyte volume 
reflected by a significant increase in the cardiomyocyte cross-sectional area (CSA) expressed in 
µm2 (p<0001, ***). This component of LVH was totally blocked by sorafenib treatment 
(p<0.0001, ***). Cardiomyocyte CSA was measured in 10 different areas per section. Results 
were obtained from 2-4 sections per rat for a total of 6 rats selected at random from each group.  
 
 
Figure 2. Sorafenib blocks interstitial collagen deposition following aortic banding. A. 
Interstitial collagen deposition following AB is evidenced by van Gieson's staining and 
predominantly localizes to perivascular spaces. Sorafenib prevents interstitial collagen 
deposition after AB. B. Quantitative measurement of tissue collagen by SirCol assay normalized 
to total protein content (µg/mg). Sorafenib blocks this component of LVH (p<0001, ***).All 
measurements were performed in duplicate. 
 
Figure 3. Sorafenib inhibits the over expression of growth factors in myocardium. Tissue 
levels are determined by ELISA normalized to total protein content (pg/mg). A. Sorafenib 
abolishes the over expression of myocardial PDGF-BB levels in banded animals (p<0001, ***). 
B. Sorafenib suppresses over expression of the pro-fibrotic growth factor TGFβ1 in myocardium 
in banded animals (p<0001, ***). All measurements were performed in duplicate. 
 
Figure 4. Sorafenib prevents phosphorylation of c-Raf and ERK1/2 in myocardium 
following AB. Left panel: representative Western blot for phosphorylated (upper band) and 
total (lower band) kinases from ventricle tissue. Right panel: ratios of phosphorylated to total 
kinases are presented as histograms. A. c-Raf phosphorylation is inhibited by sorafenib 
treatment in banded animals (p<0001, ***). B. ERK1/2 phosphorylation is blocked by sorafenib 
treatment in banded animals (p<0001, ***).  
 
Figure 5. Sorafenib regulates the increased expression of nuclear transcription factors 
resulting from AB. mRNA of c-myc (A) and c-fos (B) and GATA4 (C) are measured by reverse 
transcription quantitative polymerase chain reaction (RT-qPCR), and normalized to the 
reference gene GAPDH. Increased expression of pro-proliferative transcription factors c-myc (A) 
and c-fos (B) and pro-hypertrophic factor GATA4 (C) in AB as compared to sham-operated 
animals (p<0.0001, *** for banding vehicle versus sham vehicle for all three factors) is inhibited 
 16
by sorafenib (p<0.0001, *** for banding vehicle versus banding sorafenib for all three factors). 
All measurements were performed in duplicate. 
 
Figure 6. Sorafenib abolishes up-regulation of the pro-hypertrophic factor gene atrial 
natriuretic peptide ANP in banded animals (p<0001, ***). ANP mRNA is measured by RT-
qPCR and normalized to the reference gene GAPDH. All measurements were performed in 
duplicate. 
 
Figure 7. Schematic representation of the blocking effect of sorafenib on development of 
left ventricle hypertrophy (LVH) induced by aortic banding. Mechanical stretch induced by 
pressure overload results in over-expression of growth factors, PDGF-BB and TGFβ1 in 
myocardium [5]. The original finding of this study shows sorafenib to inhibit the up-regulation of 
these growth factors following AB. Phosphorylation and hence activation of PDGFβR and 
TGFβ1R is known to activate the downstream signaling pathway of c-Raf/ERK1/2 [10]. 
Sorafenib is reported to block phosphorylation and activation of PDGFβR and c-Raf in cancer 
studies [23]. By blocking the c-Raf/ERK1/2 cascade, sorafenib down-regulates the expression 
of pro-proliferative (c-myc, c-fos) and pro-hypertrophic (GATA4) transcription factors as well. 
One of the pro-hypertrophic effector mechanisms regulated by GATA4 is ANP [14] which is in 
turn suppressed by sorafenib treatment. The sum of the inhibitory effects of sorafenib ends at 
the suppression of cardiomyocyte hypertrophy as well as of interstitial collagen deposition, the 
two main components of LVH.  
   Blocking effect of sorafenib on expression of growth factor as demonstrated in this study 
   Blocking effect of sorafenib previously reported by Wilhelm et al. [23]  
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